Auditoriums at Burns and Crest high schools will be built thanks at $20 million in state and county money.
Every year, the state s Needs-Based Public School Capital Fund gives grants to schools and districts across North Carolina. This year the fund is providing $15 million for new auditoriums at Crest and Burns High Schools in Cleveland County. Cleveland County Schools will add $5 million in local money to the projects. Cleveland County Schools is extremely excited to learn we have been awarded the Needs-Based School Capital funds for the auditorium projects at Burns High School and Crest High School, said Stephen Fisher, Cleveland County Schools superintendent, in a press release.
Don Milani, riscoprire oggi la scrittura collettiva di Barbiana: il progetto di Scuola capitale sociale
ilfattoquotidiano.it - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from ilfattoquotidiano.it Daily Mail and Mail on Sunday newspapers.
MET - Vicchio Dalla scrittura collettiva di Don Milani alla scrittura collaborativa di oggi
cittametropolitana.fi.it - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from cittametropolitana.fi.it Daily Mail and Mail on Sunday newspapers.
Wren Therapeutics raises £12.4m in latest financing round
26th January 2021
Cambridge, UK-based biopharmaceutical company Wren Therapeutics has completed the closing of £12.4m financing, taking its total capital raised to date to around £33m.
The latest financing round was led by the company’s existing shareholder The Baupost Group, with new investors including Schooner Capital and Industry Ventures. Other existing investors, including LifeForce Capital, also participated.
Wren, a spin-off company from both the University of Cambridge in the UK and Lund University in Sweden, is focused on drug discovery and development for the treatment of protein misfolding diseases.
The company has utilised the capital raised so far to advance its lead small molecule programmes, targeting amyloid-beta and alpha-synuclein – with the first clinical candidate for amyloid-β set for Q1 2021.